Correction of side-effect content in BNF monographs for cetuximab, lenvatinib and regorafenib
Omissions of side-effects within three BNF monographs have been identified, as follows:
- Cetuximab — hypersensitivity (severe, sometimes fatal and may be delayed)
- Regorafenib — haemorrhage (sometimes fatal)
- Lenvatinib — haemorrhage (sometimes fatal)
These omissions have been corrected and the side-effects will be present in digital versions of BNF for the July 2022 monthly update and the forthcoming print edition, BNF 84 (September 2022).